Xiaopan Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaopan Wu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Xilin Zhu
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, PR China
4 shared publications- Hui Li
Department of Epidemiology Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Beijing People's Republic of China
3 shared publications - Ying Liu
School of Life Science and Technology, Inner Mongolia University of Science and Technology, Baotou 014010, China
3 shared publications Zhuo Li
Department of Infectious Disease, Affiliated Youan Hospital, Capital University of Medical Science, Beijing, PR China
3 shared publicationsLiping Pan
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, PR China
2 shared publicationsNifang Niu
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, 5 Dongdan 3 Tiao, Beijing 100005, PR China
2 shared publications
Latest Publications
- Open Access
- 23 April 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (5) , 9134-9151
PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling
Paroxysmal kinesigenic choreoathetosis (PKC) is an inherited disease of the nervous system. We previously identified PRRT2 as the causative gene of PKC. However, as little is known about the function of PRRT2, elucidating its function will benefit not only PKC studies, but also many other related disorders. Here, we reveal higher levels of glutamate in the plasma of PKC patients and the culture medium of neurons following knock-out Prrt2 expression. Using double immunostaining assays we confirm Prrt2 is located at the glutamatergic neurons in accordance with its function. Our co-immunoprecipitation assays reveal mutant PRRT2 interferes with SNAP25 and GRIA1 interactions, respectively. Furthermore, using live-labeling techniques, we confirmed co-transfection with mutant PRRT2 caused an increase in GRIA1 distribution on the cell surface. Therefore, our results suggest that mutant PRRT2, probably through its weakened interaction with SNAP25, affects glutamate signaling and glutamate receptor activity, resulting in the increase of glutamate release and subsequent neuronal hyperexcitability.
- 23 April 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (5) , 9134-9151
Open AccessPRRT2 Mutant Leads to Dysfunction of Glutamate Signaling
Paroxysmal kinesigenic choreoathetosis (PKC) is an inherited disease of the nervous system. We previously identified PRRT2 as the causative gene of PKC. However, as little is known about the function of PRRT2, elucidating its function will benefit not only PKC studies, but also many other related disorders. Here, we reveal higher levels of glutamate in the plasma of PKC patients and the culture medium of neurons following knock-out Prrt2 expression. Using double immunostaining assays we confirm Prrt2 is located at the glutamatergic neurons in accordance with its function. Our co-immunoprecipitation assays reveal mutant PRRT2 interferes with SNAP25 and GRIA1 interactions, respectively. Furthermore, using live-labeling techniques, we confirmed co-transfection with mutant PRRT2 caused an increase in GRIA1 distribution on the cell surface. Therefore, our results suggest that mutant PRRT2, probably through its weakened interaction with SNAP25, affects glutamate signaling and glutamate receptor activity, resulting in the increase of glutamate release and subsequent neuronal hyperexcitability.
- 1 February 2012
- Published by Elsevier in Antiviral Research
- Vol. 93 (2) , 297-300
Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese
- 1 February 2012
- Published by Elsevier in Antiviral Research
- Vol. 93 (2) , 297-300
Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese
- 31 March 2011
- Published by Elsevier in Antiviral Research
- Vol. 89 (3) , 189-192
Human leukocyte antigen class I and class II genes polymorphisms might be associated with interferon α therapy efficiency of chronic hepatitis B
- 31 March 2011
- Published by Elsevier in Antiviral Research
- Vol. 89 (3) , 189-192
Human leukocyte antigen class I and class II genes polymorphisms might be associated with interferon α therapy efficiency of chronic hepatitis B
- 30 September 2009
- Published by Elsevier in Antiviral Research
- Vol. 83 (3) , 252-256
A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-α treatment in chronic hepatitis B patients
- 30 September 2009
- Published by Elsevier in Antiviral Research
- Vol. 83 (3) , 252-256
A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-α treatment in chronic hepatitis B patients
- 31 January 2009
- Published by Elsevier in Clinical Biochemistry
- Vol. 42 (1-2) , 17-21
Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes
- 31 January 2009
- Published by Elsevier in Clinical Biochemistry
- Vol. 42 (1-2) , 17-21
Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes